Sai Life Sciences Faces IGST Demand of Rs. 70.15 Lakh, Plans Rectification With No Major Financial Impact
Sai Life Sciences Limited has recently issued a regulatory filing dated November 30, 2025, addressed to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Through the present regulatory filing, the company has informed the stock exchange that it has received an order dated November 12, 2025, passed by the Assistant Commissioner, Central Tax, Division-II (Pimpri), Pune-I Commissionerate under Section 74 of the CGST Act, 2017. The order raises an IGST demand of Rs. 70,15,687, Interest at applicable rates, Penalty of Rs. 70,15,687 to the company.
The company is alleged to have availed excess ITC (Input Tax Credit) and also the difference between B2B supply with the Sale/Purchase register updated on the Government Portal for the financial years 2018-19 to 2021-22.
Now, the Company is planning to file a request to correct the order. It expects a positive result and does not believe this order will have any major financial effect on the Company.
The company has disclosed the aforesaid information to the stock exchange in pursuance of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), read with the SEBI Circular on the Industry Standards Note on Regulation 30 dated February 25, 2025.
